Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for NF1-related internal plexiform neurofibromas
NCT01412892Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2011
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus in neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Radiographic response assessed by MRI analysis at 1 year. Started Apr 2011; status: completed.
02
Drugs
everolimus
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NCT01412892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01412892.